Titanium nano-scale etching on an implant surface

Information

  • Patent Grant
  • 10765494
  • Patent Number
    10,765,494
  • Date Filed
    Monday, December 17, 2018
    5 years ago
  • Date Issued
    Tuesday, September 8, 2020
    3 years ago
Abstract
A method of forming an implant to be implanted into living bone is disclosed. The method comprises the act of roughening at least a portion of the implant surface to produce a microscale roughened surface. The method further comprises the act of immersing the microscale roughened surface into a solution containing hydrogen peroxide and a basic solution to produce a nanoscale roughened surface consisting of nanopitting superimposed on the microscale roughened surface. The nanoscale roughened surface has a property that promotes osseointegration.
Description
FIELD OF THE INVENTION

This invention relates generally to implants and, in particular, to a dental implant having a nanometer-scale surface topography and methods of making same.


BACKGROUND OF THE INVENTION

It is becoming more common to replace a missing tooth with a prosthetic tooth that is placed upon and attached to a dental implant. Dental implants are often comprised of metal and metal alloys, including titanium (Ti) and titanium alloys. The dental implant serves as an artificial root that integrates with the gingiva and the bone tissue of the mouth.


For the dental implant to function successfully, sufficient osseointegration is required. In other words, a bond between the implant and the bone must be formed and retained. The surface of the implant may be roughened to help enhance the osseointegration process. Non-limiting examples of processes for roughening an implant surface include acid etching and grit blasting, which impart roughness on the surface.


Other existing techniques involve forming a generally thin (e.g., generally less than 10 microns) coating of osseointegration materials, such as hydroxyapatite (HA), other calcium phosphates, or other osseointegration compounds, for forming a direct chemical compound between the implant and the bone. Plasma spraying and sputtering are two major techniques that have been used to deposit, for example, HA, onto an implant.


U.S. Pat. App. Pub. Nos. 2008/0220394, 2007/0110890, and 2007/0112353 disclose methods of discrete deposition of hydroxyapatite crystals to impart a nano-scale topography. Although effective, the disclosed processes require that a residual substance (i.e. HA crystals) be left on the surface post-processing in order to impart a nano-scale topography into the surface.


The present invention is directed to an improved implant having nanometer-scale surface topography directly imparted into the surface for improving the rate and extent of osseointegration, and methods of making the same.


SUMMARY OF THE INVENTION

The present invention relates to a method of forming an implant to be implanted into living bone. The method comprises the acts of roughening at least a portion of the implant surface to produce a microscale roughened surface. The method further comprises the act of immersing the microscale roughened surface into a solution containing hydrogen peroxide and a basic solution to produce a nanoscale roughened surface consisting of nanopitting superimposed on the microscale roughened surface.


In another aspect, another method of forming an implant to be implanted into living bone is disclosed. The method comprises the act of removing a native oxide layer from at least a portion of the implant surface. The method further comprises the act of roughening at least the portion of the implant surface to produce a microscale roughened surface. The method further comprises the act of rinsing the microscale roughened surface in deionized water. The method further describes the act of immersing the microscale roughened surface into a solution containing hydrogen peroxide and a basic solution at a high pH level to produce a nanoscale roughened surface consisting of nanopitting superimposed on the microscale roughened surface. The method further comprises the acts of passivating the nanoscale roughened surface with nitric acid, and rinsing the nanoscale roughened surface in deionized water.


The above summary of the present invention is not intended to represent each embodiment, or every aspect, of the present invention. This is the purpose of the figures and the detailed description which follow.





BRIEF DESCRIPTION OF THE DRAWINGS

The foregoing and other advantages of the invention will become apparent upon reading the following detailed description and upon reference to the drawings.



FIG. 1 is a side view of an implant according to one embodiment.



FIGS. 2a, 2b, and 2c, are a side view, an insertion end view, and a gingival end view, receptively, of an implant according to a second embodiment.



FIGS. 3a, 3b, and 3c, are a side view, an insertion end view, and a gingival end view, respectively, of an implant according to a third embodiment.



FIGS. 4a and 4b are a side view, an end view, and a cross-sectional view, respectively, of an implant according to a fourth embodiment.



FIG. 5 is a flow diagram detailing a method of forming an implant according to an embodiment of the present invention.



FIG. 6 is a side view of the implant in FIG. 1 with a roughened outer surface.



FIG. 7a is a flow diagram detailing a method of forming an implant according to another embodiment of the present invention.



FIG. 7b is a flow diagram detailing a method of forming an implant according to yet another embodiment of the present invention.



FIG. 8a is a scanning electron microscope (SEM) image showing a commercially pure titanium implant post-acid etching at 2 kX.



FIG. 8b is a field emission scanning electron microscope (FESEM) image showing a commercially pure titanium implant post-acid etching at 30 kX.



FIG. 9a is an FESEM image showing a commercially pure titanium implant post-KOH/H2O2 treatment at 2 kX using a method of the present invention.



FIG. 9b is an FESEM image showing a commercially pure titanium implant post-KOH/H2O2 treatment at 30 kX using a method of the present invention.



FIG. 9c is an FESEM image showing a commercially pure titanium implant post-KOH/H2O2 treatment at 100 kX using a method of the present invention.





DETAILED DESCRIPTION OF THE INVENTION

The present invention is directed to implants having a nanometer scale surface topography consisting of irregular shaped pitting and methods of making the same. An implant in the context of the present invention means a device intended to be placed within a human body such as to connect skeletal structures (e.g., a hip implant) or to serve as a fixture for a body part (e.g., a fixture for an artificial tooth). Although the remainder of this application is directed to a dental implant, it is contemplated that the present invention may also be applied to other (e.g., medical) implants.



FIG. 1 shows a standard dental implant 10 that includes an head portion 12, a lowermost end 14, and a threaded bottom portion 16. The implant 10 may, for example, be made of titanium, tantalum, cobalt, chromium, stainless steel, or alloys thereof. FIGS. 2a-c, 3a-c, and 4a-b, which are discussed below, describe alternative implant designs that may also be used with the present invention.


In the implant 10 of FIG. 1, the head portion 12 includes a non-rotational feature. In the embodiment shown, the non-rotational feature includes a polygonal boss 20 that may be engageable with a tool that screws the implant 10 into bone tissue. In the illustrated embodiment, the polygonal boss 20 is hexagonal. The polygonal boss 20 may also be used for non-rotationally engaging a correspondingly shaped socket on a restorative or prosthetic component that is attached to the implant 10.


The exterior of the threaded bottom portion 16 facilitates bonding with bone or gingiva. The threaded bottom section 16 includes a thread 18 that makes a plurality of turns around the implant 10. The threaded bottom portion 16 may further include a self-tapping region with incremental cutting edges 17 that allows the implant 10 to be installed without the need for a bone tap. These incremental cutting edges 17 are described in detail in U.S. Pat. No. 5,727,943, entitled “Self-Tapping, Screw-Type Dental Implant,” which is incorporated by reference in its entirety.



FIGS. 2a-c disclose an implant 36 that differs from the implant 10 of FIG. 1 in the details of the cutting edges 17′ and the contours of the threads defining the exterior of the threaded bottom portion 16′. When viewed in the cross-section (see FIG. 1b), the threaded outer surface 16′ is non-circular in the region of the threads and/or the troughs between the threads. This type of thread structure is described in detail in U.S. Pat. No. 5,902,109, entitled “Reduced Friction. Screw-Type Dental Implant,” which is incorporated by reference in its entirety.


In FIGS. 3a-c, an implant 41 having a wide diameter in the region of the threaded bottom portion 42 is illustrated. The diameter is in the range of from about 4.5 mm to about 6.0 mm with the diameter of 5.0 mm being a fairly common dimension for a wide diameter implant. Such an implant 41 is useful to engage one or both cortical bones to provide enhanced stability, especially during the period of time after installation.



FIGS. 4a-b illustrate an implant 110 according to another embodiment that may be used with the present invention. The implant 110 includes a middle section 114 designed to extend through the gingiva. Preferably, it is a smooth surface that includes a titanium nitride coating so the underlying titanium or titanium alloy is not readily seen through the gingiva. The implant 110 also includes a threaded portion 120 that may include various thread structures and is preferably roughened to increase the osseointegration process. It is contemplated that implants other than those illustrated in FIGS. 1-4 may be used with the present invention.


According to embodiments of the present invention, a nanoscale roughened surface is superimposed onto a microscale roughened surface on at least a portion (e.g., the threaded bottom portion) of the surface of an implant. In one embodiment, the nanoscale roughened surface is created by immersing the microscale roughened surface into a solution containing hydrogen peroxide and a basic solution. Non-limiting examples of suitable basic solutions include potassium hydroxide solutions and sodium hydroxide solutions.


Turning now to FIG. 5, a general method of producing a nanoscale roughened surface on an implant is set forth according to one embodiment of the present invention. At step 500, an implant is provided. At least a portion of the implant surface is roughened to a microscale roughness at step 501, for example, by machining, acid etching and/or grit blasting the implant surface. As an example, FIG. 6 shows the implant 10 of FIG. 1 having a roughened surface 630. Nanopitting is then created on the microscale roughened surface by immersion into a solution containing hydrogen peroxide and a basic solution, to produce a nanoscale roughened surface on the implant at step 502.


Referring now to FIG. 7a, another general method of forming an implant according to another embodiment of the present invention is illustrated. An implant comprised of titanium, a titanium alloy (e.g. titanium 6AL-4V ELI alloy), stainless steel, or the like is provided at step 750. At step 754, nanopitting is created on a microscale roughened surface to produce a nanoscale roughened surface on the implant. At step 756, the implant is passivated with nitric acid. The implant may then be rinsed in reverse osmosis/deionized (RO/DI) water to remove residual solvents and hydroxyapatite at step 758. The implant is then dried at step 764 and sterilized at step 766 using, for example, gamma sterilization techniques.


Referring to FIG. 7b, a more detailed method of producing a nanoscale roughened surface on an implant is illustrated according to another embodiment of the present invention. A threaded dental implant comprised of titanium, a titanium alloy (e.g. titanium 6AL-4V ELI alloy), stainless steel, or the like is provided at step 700. The surface of the implant is generally clean and dry. A threaded bottom portion of the implant is etched to remove a native oxide layer from the implant surface at step 701. The native oxide layer may be removed by a first acid solution, which may include aqueous hydrofluoric acid. The threaded bottom portion is then acid etched form a microscale roughened surface at step 702. “Microscale,” as used herein, should be understood to describe an article or feature generally measured in microns such as, for example, 1 micron to 100 microns. Acid etching may result from immersion in a mixture of sulfuric and hydrochloric acids, creating peak-to-peak and peak-to-valley irregularity distances in the microscale roughened surface of about 1 micron to 3 microns. This type of roughening method utilized on commercially pure (CP) titanium is described in detail in U.S. Pat. No. 5,876,453, entitled “Implant Surface Preparation,” which is incorporated by reference in its entirety. An additional roughening method utilized on Titanium 6AL-4V ELI alloy is described in detail in U.S. Pat. App. Pub. No. 2004/0265780, entitled “Surface Treatment Process for Implants Made of Titanium Alloy.” which is also incorporated by reference in its entirety. It is contemplated that other surface roughening techniques including, but not limited to, grit blasting, titanium plasma spraying, and combinations thereof, may be used. Grit blasting the threaded bottom portion to form a microscale roughened surface generally results in peak-to-peak and peak-to-valley irregularity distances of about 10 microns to 30 microns. Grit blasting and acid etching the threaded bottom portion to form the microscale roughened surface generally results in both levels of topographies, i.e., with about 1 micron to 3 microns peak-to-peak and peak-to-valley irregularity distances superimposed on 10 microns to 30 microns peak-to-peak and peak-to-valley irregularity distances on the microscale roughened surface.


At step 703, the microscale roughened surface is immersed into a solution containing hydrogen peroxide and a basic solution to produce a nanoscale roughened surface consisting of nanopitting superimposed on the microscale roughened surface. The basic solution can be any base with a pH in the range of about 7 to about 14, and preferably about 14, such as potassium hydroxide or sodium hydroxide. “Nanoscale,” as used herein, should be understood to describe an article or feature generally measured in nanometers such as, for example, 1 nanometer to 500 nanometers. Generally, immersion into the hydrogen peroxide/basic solution results in nanopitting of about 1 nanometer to about 100 nanometers.


Immersion time, hydrogen peroxide concentration, and basic solution concentration are among several factors that affect the rate and amount of nanopitting superimposed onto the microscale roughness of the implant surface. For example, immersing a commercially pure titanium implant in a solution of 3-5% potassium hydroxide and 13-22% hydrogen peroxide for 1 minute at 50 degrees Celsius typically results in an acceptable nanoscale roughness of the implant surface. Longer immersion times may impact the micron level topographies, while potassium hydroxide concentrations of less than 3% and/or hydrogen peroxide concentrations of less than 13% may result in the nano-topography not being adequately formed.


Another factor affecting the rate and amount of nanopitting onto the microscale roughness of the implant surface is the processing temperature. At temperatures of higher than about 60 degrees Celsius, for example, the etching is accelerated and can begin to impact the micron level topographies. Thus, it may be desirable for the processing temperature to be maintained at or below about 60 degrees Celsius.


Processing temperature, immersion time, and/or chemical concentration may be adjusted to compensate for one or more of these variables being within an otherwise unacceptable range, in order to nevertheless produce acceptable nano-topography. For example, potassium hydroxide concentrations of less than 3% may be adjusted by increasing immersion time and/or processing temperature in order to produce an acceptable amount of nanopitting on the microscale roughness of the implant surface.


Post-processing, the implant is passivated with nitric acid at step 704. At step 705, the implant is rinsed in hot deionized water (e.g. 70 degrees Celsius to 100 degrees Celsius) to remove any acid residuals and to potentially enhance titanium hydroxide groups on the surface.


Hydroxyapatite (HA) nanocrystals may then optionally be deposited on the nanoscale roughened surface of the implant at step 706. The HA nanocrystals may be introduced onto the nanoscale roughened surface of the implant in the form of a colloid. A representative amount of HA in the colloid is typically in the range of about 0.01 weight percent to about 1 weight percent (e.g., 0.10 weight percent). To form the colloid, HA nanocrystals may be combined in solution with a 2-methoxyethanol solvent and ultrasonically dispersed and deagglomerated. The pH of the colloidal solution may be adjusted with sodium hydroxide, ammonium hydroxide, or the like on the other of about 7 to about 13. As such, the colloidal solution may include HA nanocrystals, 2-methoxyethanol, and a pH adjuster (e.g. ammonium hydroxide, and/or sodium hydroxide). This type of HA deposition is described in detail in U.S. Pat. App. Pub. Nos. 2007/0110890 and 2007/0112353, both entitled “Deposition of Discrete Nanoparticles on an Implant Surface,” which are incorporated by reference in their entireties. The implant may then be rinsed in reverse osmosis/deionized (RO/DI) water to remove residual solvent and HA at step 708.


Alternatively or in addition to the acts of depositing HA nanocrystals at step 706 and rinsing at step 708, a sodium lactate coating may be applied on the nanoscale roughened surface of the implant at step 707 and the implant rinsed at step 708. In either embodiment, the implant may then be dried (e.g., oven dried), at step 714, and sterilized at step 716 using, for example, gamma sterilization.


The implant surface may be characterized utilizing Field Emission Scanning Electron microscopy (FESEM). Depending upon the resolution of the instrument, the nanopitting may typically be witnessed at magnifications of 30 kX or higher. As discussed above, the nanopitting generally has a distribution in the range of about 1 nanometer to about 500 nanometers, and typically between about 1 nanometer and about 100 nanometers.


Example 1


FIGS. 8a and 8b are scanning electron microscope images showing a micron-level roughness imparted by an acid etching process on a commercially pure titanium implant. The image of FIG. 8a was taken at 2 kX utilizing an SEM. The image of FIG. 8b was taken at 30 kX utilizing an FESEM.


The implant shown in FIGS. 8a and 8b was machined, cleaned, and acid etched to impart a microscale roughness on the surface of the implant using a process similar to that described in U.S. Pat. No. 5,603,338, herein incorporated by reference in its entirety. The native oxide layer of the implant was removed via immersion in a hydrofluoric acid solution of about 5% v/v (about 8.5% w/w) for about 60 seconds at about 20-25 degrees Celsius. The acid etching was accomplished by immersion in an H2SO4/HCl solution for about 7 minutes at about 60-70 degrees Celsius. FIG. 8a demonstrates the micron-level topography imparted by this acid etching at a magnification of 2 kX. Characteristic 1-3 micron peak-to-peak micropitting is clearly defined. FIG. 8b, which is an FESEM image of the surface at a magnification of 30 kX, demonstrates the general lack of nanometer-scale surface roughness features after this level of processing.


The implant was then immersed in about 4% w/w potassium hydroxide and about 16% w/w hydrogen peroxide at a starting temperature of about 50 degrees Celsius for about 1 minute, according to one embodiment of the invention. Post-processing, the implant was thoroughly rinsed in de-ionized water, then passivated through 40 kHz ultrasonic immersion in about 22, w/w nitric acid for about 10 minutes at about 60 degrees Celsius, followed by additional rinsing in de-ionized water, and oven drying at about 100-150 degrees Celsius.


The additional processing imparted a nanometer level topography, as demonstrated in the FESEM images of FIGS. 9a-c. FIG. 9a, which is an FESEM image at a magnification of 2 kX, demonstrates the micron-level roughness imparted by the acid etching remains on the implant, including the characteristic 1-3 micron peak-to-peak micropitting. The nanoscale roughness cannot be witnessed at this magnification.



FIG. 9b, which shows the surface of FIG. 9a at a magnification of 30 kX, demonstrates the nanoscale roughness features of the implant surface. Nanopitting in the 1-100 nanometer range can be witnessed at this magnification. FIG. 9c, which is a magnification of the surface of FIGS. 9a and 9b at 100 kX, more clearly demonstrates the resultant nanoscale roughness.


The implant shown in FIGS. 9a-c was then evaluated for surface chemistry utilizing Electron Dispersion Spectroscopy. A spot size of approximately 275×375 microns was analyzed for chemistry. The freshly processed and passivated sample demonstrated a 100% titanium surface chemistry, indicating that no residuals were present at the detection limit of the instrument.


Example 2

All of the solutions containing the concentrations of KOH and H2O2 provided in Table 1 below resulted in acceptable nano-topography on commercially pure titanium with about 1 minute exposure to a hydrogen peroxide and potassium hydroxide solution at about 50 degrees Celsius:









TABLE 1







Concentrations of KOH and H2O2










% KOH
% H2O2







4
16



4
19



4
22



3
16



3
19



5
13



5
19










A solution having about 4% w/w KOH and about 16% w/w H2O2 resulted in acceptable nano-topography on titanium 6AL-4V ELI with 1 minute exposure to a hydrogen peroxide and potassium hydroxide solution at about 50 degrees Celsius.


A solution having about 4% w/w NaOH and about 16% w/w H2O2 resulted in acceptable nano-topography on titanium 6AL-4V ELI with about 1 minute exposure to a hydrogen peroxide and sodium hydroxide solution at about 50 degrees Celsius.


Example 3

All of the solutions containing the concentrations of KOH and H2O2 provided in Table 2 below, with KOH and H2O2 concentrations ranging from about 1% w/w to about 6% w/w resulted in acceptable nano-topography on grit-blasted and acid-etched commercially pure titanium with about 4 minute exposure to a hydrogen peroxide and potassium hydroxide solution at about 33 degrees Celsius.









TABLE 2







Concentrations of KOH and H2O2










% KOH
% H2O2







4
1



4
3



4
3



4
4



4
5



4
6



1
4



2
4



3
4



5
4



6
4










The solutions containing the concentrations of KOH and H2O2 provided in Table 2 slow down the method of forming acceptable nano-topography, thus improving process control in the production environment. As the base or peroxide concentration approached 0% w/w, the desired surface topography was not formed.


It is contemplated that various combinations of variables (e.g., concentration of basic solution, concentration of hydrogen peroxide, exposure times, temperatures) may be used to forms the desired surface attributes. According to one non-limiting example, the desired surface may be obtained using 4.1% KOH, 3.85, H2O2, 3 minute exposure time, and 31 degrees Celsius.


While the present invention has been generally described relative to the part of the implant contacting bone tissue, it is contemplated that the acts of etching, acid etching, roughening, nanopitting, and depositing herein described may be performed on the entire implant.


While the present invention has been described with reference to one or more particular embodiments, those skilled in the art will recognize that many changes may be made thereto without departing from the spirit and scope of the present invention. Each of these embodiments and obvious variations thereof is contemplated as falling within the spirit and scope of the claimed invention, which is set forth in the following claims.

Claims
  • 1. A method of forming an implant to be implanted into living bone, the method comprising: acid etching at least a portion of the implant surface to produce a microscale roughened surface; andtreating the microscale roughened surface to provide a nanoscale topography superimposed on the microscale roughened surface, wherein treating the microscale roughened surface to include the nanoscale topography includes immersing the implant in a solution including hydrogen peroxide and a basic solution.
  • 2. The method of claim 1, wherein the basic solution is a potassium hydroxide solution.
  • 3. The method of claim 1, wherein the basic solution is a sodium hydroxide solution.
  • 4. The method of claim 1, wherein the nanoscale roughened surface includes nanopitting.
  • 5. The method of claim 1, further including: depositing discrete nanoparticles on the nanoscale roughened surface, the nanoscale roughened surface including nanopitting.
  • 6. The method claim 1, wherein, prior to acid etching, the method includes: removing the native oxide layer from least the portion of the implant surface.
  • 7. A method of forming an implant to be implanted into living bone, the method comprising: roughening at least a portion of the implant surface to produce a dual microscale roughened surface including a first microscale surface having first peak-to-valley distances and a second microscale surface superimposed on the first microscale surface, the second microscale surface having second peak-to-valley distances that are less than the first peak-to-valley distances; andtreating the dual microscale roughened surface to provide a nanoscale topography superimposed on the dual microscale roughened surface.
  • 8. The method of claim 7, roughening at least the portion of the implant surface includes: grit blasting the portion of the implant surface to form the first microscale surface.
  • 9. The method of claim 8, wherein the first peak-to-valley distances of the first microscale surface are about 10 microns to 30 microns.
  • 10. The method of claim 8, wherein roughening at least the portion of the implant surface includes: acid etching the first microscale surface to form the second microscale surface superimposed on the first microscale surface.
  • 11. The method of claim 10, wherein the second peak-to-valley distances of the second microscale surface are less than 10 microns.
  • 12. The method of claim 10, wherein the second peak-to-valley distances of the second microscale surface are about 1 micron to about 3 microns.
  • 13. The method of claim 10, wherein the second microscale surface includes micropitting superimposed on the grit blasted surface.
  • 14. The method of claim 7, wherein treating the dual microscale roughened surface to include the nanoscale topography includes immersing the implant in a solution including hydrogen peroxide and a basic solution.
  • 15. The method of claim 14, wherein the basic solution is a potassium hydroxide solution.
  • 16. The method of claim 14, wherein the basic solution is a sodium hydroxide solution.
  • 17. The method of claim 7, wherein the nanoscale roughened surface includes nanopitting.
  • 18. The method of claim 17, further including: depositing discrete nanoparticles on the nanoscale roughened surface.
  • 19. The method claim 7, wherein, prior to roughening at least the portion of the implant, the method includes: removing the native oxide layer from at least the portion of the implant surface.
RELATED APPLICATION

This application claims the benefit of U.S. Provisional Application No. 61/318,641, filed Mar. 29, 2010.

US Referenced Citations (264)
Number Name Date Kind
3603288 Case et al. Sep 1971 A
3772355 Merz Nov 1973 A
3984914 Schwartz Oct 1976 A
4097935 Jarcho Jul 1978 A
4131597 Bluethgen et al. Dec 1978 A
4145764 Suzuki et al. Mar 1979 A
4146936 Aoyagi et al. Apr 1979 A
4223412 Aoyagi et al. Sep 1980 A
4321042 Scheicher Mar 1982 A
4330891 Branemark et al. May 1982 A
4366183 Ghommidh et al. Dec 1982 A
4403941 Okiura et al. Sep 1983 A
4451235 Okuda et al. May 1984 A
4538306 Dorre et al. Sep 1985 A
4636526 Dorman et al. Jan 1987 A
4687487 Hintermann Aug 1987 A
4746532 Suzuki et al. May 1988 A
4818559 Hama et al. Apr 1989 A
4830993 Legrand et al. May 1989 A
4846837 Kurze et al. Jul 1989 A
4847163 Shimamune et al. Jul 1989 A
4863474 Brown et al. Sep 1989 A
4871578 Adam Oct 1989 A
4879136 Polz Nov 1989 A
4880610 Constantz Nov 1989 A
4882196 Shimamune et al. Nov 1989 A
4904534 Nagai Feb 1990 A
4908030 Linkow et al. Mar 1990 A
4909846 Barfurth et al. Mar 1990 A
4911953 Hosonuma et al. Mar 1990 A
4929589 Martin et al. May 1990 A
4944754 Linkow et al. Jul 1990 A
4960646 Shimamune et al. Oct 1990 A
4965088 Shimamune et al. Oct 1990 A
4988362 Toriyama et al. Jan 1991 A
4990163 Ducheyne et al. Feb 1991 A
5030474 Saita et al. Jul 1991 A
5068122 Kokubo et al. Nov 1991 A
5071351 Green, Jr. et al. Dec 1991 A
5071434 Tsuzuki et al. Dec 1991 A
5071436 Hue et al. Dec 1991 A
5077132 Maruno et al. Dec 1991 A
5092890 Pohlemann et al. Mar 1992 A
5128169 Saita et al. Jul 1992 A
5134009 Ichitsuka et al. Jul 1992 A
5141576 Shimamune et al. Aug 1992 A
5180426 Sumita Jan 1993 A
5185208 Yamashita et al. Feb 1993 A
5188670 Constantz Feb 1993 A
5196201 Larsson et al. Mar 1993 A
5205921 Shirkanzadeh Apr 1993 A
5219361 Von Recum et al. Jun 1993 A
5231151 Spencer et al. Jul 1993 A
5263491 Thornton Nov 1993 A
5279720 Divigalpitiya Jan 1994 A
5279831 Constantz et al. Jan 1994 A
5286571 Mirkin et al. Feb 1994 A
5344457 Pilliar et al. Sep 1994 A
5344654 Rueger et al. Sep 1994 A
5358529 Davidson Oct 1994 A
5364522 Wang Nov 1994 A
5397642 Li et al. Mar 1995 A
5456723 Steinemann et al. Oct 1995 A
5478237 Ishizawa Dec 1995 A
5484286 Hansson Jan 1996 A
5501706 Arenberg Mar 1996 A
5522893 Chow et al. Jun 1996 A
5527837 Kondou et al. Jun 1996 A
5543019 Lee et al. Aug 1996 A
5558517 Shalaby et al. Sep 1996 A
5571188 Ellingsen Nov 1996 A
5580429 Chan et al. Dec 1996 A
5580819 Li et al. Dec 1996 A
5584875 Duhamel et al. Dec 1996 A
5603338 Beaty Feb 1997 A
5607607 Naiman et al. Mar 1997 A
5609633 Kokubo Mar 1997 A
5612049 Li et al. Mar 1997 A
5639402 Barlow et al. Jun 1997 A
5652016 Imura et al. Jul 1997 A
5700289 Breitbart et al. Dec 1997 A
5722439 Endelson Mar 1998 A
5726524 Debe Mar 1998 A
5730598 Story et al. Mar 1998 A
5733564 Lehtinen Mar 1998 A
5759376 Teller et al. Jun 1998 A
5759598 Gaier Jun 1998 A
5763092 Lee et al. Jun 1998 A
5766247 Aoki et al. Jun 1998 A
5766669 Pugh et al. Jun 1998 A
5767032 Hokkanen et al. Jun 1998 A
5772439 Yamaoka et al. Jun 1998 A
5807430 Zheng et al. Sep 1998 A
5811151 Hendriks et al. Sep 1998 A
5817326 Nastasi et al. Oct 1998 A
5858318 Luo Jan 1999 A
5871547 Abouaf et al. Feb 1999 A
5888034 Greenberg Mar 1999 A
5934287 Hyashi et al. Aug 1999 A
5947893 Agrawal et al. Sep 1999 A
5952399 Rentsch Sep 1999 A
5958340 Meyer Sep 1999 A
5958504 Lee et al. Sep 1999 A
5962549 Bonfield et al. Oct 1999 A
5981619 Shikinami et al. Nov 1999 A
5990381 Nishihara Nov 1999 A
6013591 Ying et al. Jan 2000 A
6051272 Stupp et al. Apr 2000 A
6069295 Leitao May 2000 A
6077989 Kandel et al. Jun 2000 A
6118043 Nies et al. Sep 2000 A
6129928 Sarangapani et al. Oct 2000 A
6136369 Leitao et al. Oct 2000 A
6139585 Li et al. Oct 2000 A
6143037 Goldstein et al. Nov 2000 A
6143948 Leitao et al. Nov 2000 A
6146686 Leitao Nov 2000 A
6146767 Schwartz Nov 2000 A
6153266 Yokogawa et al. Nov 2000 A
6153664 Wise et al. Nov 2000 A
6183255 Oshida Feb 2001 B1
6190412 Lee et al. Feb 2001 B1
6200137 Holand et al. Mar 2001 B1
6206598 Johnson et al. Mar 2001 B1
6207218 Layrolle et al. Mar 2001 B1
6214049 Gayer et al. Apr 2001 B1
6221111 Piveteau et al. Apr 2001 B1
6261322 Despres, III et al. Jul 2001 B1
6270347 Webster et al. Aug 2001 B1
6280474 Cassidy et al. Aug 2001 B1
6280789 Rey et al. Aug 2001 B1
6280863 Frank et al. Aug 2001 B1
6290982 Seppala et al. Sep 2001 B1
6306784 Drescher et al. Oct 2001 B1
6306925 Clupper et al. Oct 2001 B1
6309660 Hsu et al. Oct 2001 B1
6338810 Carpena et al. Jan 2002 B1
6344061 Ribreiro De Sousa Fidalgo Leitao et al. Feb 2002 B1
6344209 Saito et al. Feb 2002 B1
6344276 Lin et al. Feb 2002 B1
6372354 Park et al. Apr 2002 B1
6395299 Babich et al. May 2002 B1
6399215 Zhu et al. Jun 2002 B1
6419708 Hall et al. Jul 2002 B1
6426114 Troczynski et al. Jul 2002 B1
6428803 Ewers et al. Aug 2002 B1
6491723 Beaty Dec 2002 B1
6508838 Lee et al. Jan 2003 B2
6518328 Kumar Feb 2003 B2
6527849 Dry Mar 2003 B2
6527938 Bales et al. Mar 2003 B2
6530958 Cima et al. Mar 2003 B1
6544732 Chee et al. Apr 2003 B1
6569292 Coffer May 2003 B2
6569489 Li May 2003 B1
6589365 Ito Jul 2003 B2
6589590 Czernuszka et al. Jul 2003 B2
6596338 Scott et al. Jul 2003 B2
6617142 Keogh et al. Sep 2003 B2
6620861 Nakatuka et al. Sep 2003 B1
6645644 Schwartz et al. Nov 2003 B1
6652765 Beaty Nov 2003 B1
6689170 Larsson et al. Feb 2004 B1
6709379 Brandau et al. Mar 2004 B1
6733503 Layrolle et al. May 2004 B2
6740366 Hori et al. May 2004 B2
6790455 Chu et al. Sep 2004 B2
6812471 Popiolkowski et al. Nov 2004 B2
6853075 Auner et al. Feb 2005 B2
6919070 Rudin et al. Jul 2005 B1
6960249 Lin et al. Nov 2005 B2
6969474 Beaty Nov 2005 B2
6969501 Sapieszko et al. Nov 2005 B2
6991803 Sapieszko et al. Jan 2006 B2
7007872 Yadav et al. Mar 2006 B2
7018418 Amrich et al. Mar 2006 B2
7067169 Liu et al. Jun 2006 B2
7067577 Aramaki et al. Jun 2006 B2
7083642 Sirhan et al. Aug 2006 B2
7087086 Li et al. Aug 2006 B2
7105030 Despres, III et al. Sep 2006 B2
7112063 Bulard et al. Sep 2006 B2
7169317 Beaty Jan 2007 B2
7341756 Liu Mar 2008 B2
8641418 Mayfield Feb 2014 B2
9034201 Mayfield May 2015 B2
9283056 Mayfield et al. Mar 2016 B2
9757212 Mayfield et al. Sep 2017 B2
10182887 Mayfield Jan 2019 B2
20010020476 Gan et al. Sep 2001 A1
20020016635 Despres, III et al. Feb 2002 A1
20020018798 Sewing et al. Feb 2002 A1
20020028424 Prestipino et al. Mar 2002 A1
20020119325 Park et al. Aug 2002 A1
20020127391 Kumar Sep 2002 A1
20030005646 McHale, Jr. Jan 2003 A1
20030082232 Lee et al. May 2003 A1
20030099762 Zhang et al. May 2003 A1
20030170378 Wen et al. Sep 2003 A1
20030175773 Chee et al. Sep 2003 A1
20030219466 Kumta et al. Nov 2003 A1
20030219562 Rypacek et al. Nov 2003 A1
20030231984 Bright et al. Dec 2003 A1
20040023048 Schwartz et al. Feb 2004 A1
20040024081 Trieu et al. Feb 2004 A1
20040053197 Minevski et al. Mar 2004 A1
20040053198 Minevski et al. Mar 2004 A1
20040053199 Minevski et al. Mar 2004 A1
20040121290 Minevski et al. Jun 2004 A1
20040121451 Moritz et al. Jun 2004 A1
20040145053 Auner et al. Jul 2004 A1
20040149586 Sul Aug 2004 A1
20040153165 Li et al. Aug 2004 A1
20040210309 Denzer et al. Oct 2004 A1
20040214326 Cousins et al. Oct 2004 A1
20040234604 Mecking et al. Nov 2004 A1
20040241613 Jansen et al. Dec 2004 A1
20040249472 Liu et al. Dec 2004 A1
20040258726 Stupp et al. Dec 2004 A1
20040265780 Robb et al. Dec 2004 A1
20050008620 Shimp et al. Jan 2005 A1
20050019365 Frauchiger et al. Jan 2005 A1
20050031704 Ahn Feb 2005 A1
20050038498 Dubrow et al. Feb 2005 A1
20050084513 Tang Apr 2005 A1
20050100937 Holmes May 2005 A1
20050113834 Breitenstien et al. May 2005 A1
20050113936 Brustad et al. May 2005 A1
20050175670 Aoyagi et al. Aug 2005 A1
20050211680 Li et al. Sep 2005 A1
20050226939 Ramalingam et al. Oct 2005 A1
20050249654 Chow Nov 2005 A1
20060039951 Sapieszko et al. Feb 2006 A1
20060105015 Perla et al. May 2006 A1
20060110306 Chow et al. May 2006 A1
20060141002 Liu et al. Jun 2006 A1
20060178751 Despres, III et al. Aug 2006 A1
20060229715 Istephanous et al. Oct 2006 A1
20060246105 Molz et al. Nov 2006 A1
20060257358 Wen et al. Nov 2006 A1
20060257492 Wen et al. Nov 2006 A1
20070010893 Wen et al. Jan 2007 A1
20070184299 Wei Aug 2007 A1
20070190107 Tosatti et al. Aug 2007 A1
20080206554 Riman et al. Aug 2008 A1
20080213726 Schlottig et al. Sep 2008 A1
20080216926 Guo Sep 2008 A1
20080220394 Berckmans Sep 2008 A1
20090120457 Naghshineh et al. May 2009 A1
20090132048 Denzer May 2009 A1
20090191507 Charlton et al. Jul 2009 A1
20100136506 Park Jun 2010 A1
20100179665 Schlottig et al. Jul 2010 A1
20100260922 Owens et al. Oct 2010 A1
20110008753 Rupprecht et al. Jan 2011 A1
20110059312 Howling et al. Mar 2011 A1
20110104638 Schlottig et al. May 2011 A1
20120328905 Guo et al. Dec 2012 A1
20130045360 Ibacache Feb 2013 A1
20130196289 Schwarz et al. Aug 2013 A1
20130209951 Piascik et al. Aug 2013 A1
20160184059 Mayfield et al. Jun 2016 A1
20170100797 Guo et al. Apr 2017 A1
20170360532 Mayfield et al. Dec 2017 A1
Foreign Referenced Citations (18)
Number Date Country
6220565 Feb 1967 AU
6227170 Sep 2006 AU
2599269 Sep 2006 CA
2600718 Sep 2006 CA
3516411 Nov 1986 DE
0450939 Oct 1991 EP
0450939 Jan 1997 EP
1275422 Jan 2003 EP
1502570 Feb 2005 EP
2045083 Oct 1980 GB
0218463 Jan 1990 JP
05224448 Sep 1993 JP
WO-9513101 May 1995 WO
WO-9513102 May 1995 WO
WO-9639202 Dec 1996 WO
WO-2006096793 Sep 2006 WO
WO-2006102347 Sep 2006 WO
WO-2007035217 Mar 2007 WO
Non-Patent Literature Citations (26)
Entry
“U.S. Appl. No. 13/074,670, Final Office Action dated Aug. 6, 2013”, 9 pgs.
“U.S. Appl. No. 13/074,670, Non-Final Office Action dated Mar. 11, 2013”, 8 pgs.
“U.S. Appl. No. 13/074,670, Notice of Allowance dated Oct. 10, 2013”, 9 pgs.
“U.S. Appl. No. 13/074,670, Preliminary Amendment filed Mar. 11, 2013”, 6 pgs.
“U.S. Appl. No. 13/074,670, Response filed Jul. 11, 2013 to Non-Final Office Action dated Mar. 11, 2013”, 10 pgs.
“U.S. Appl. No. 13/074,670, Response filed Oct. 2, 2013 to Final Office Action dated Aug. 6, 2013”, 12 pgs.
“U.S. Appl. No. 14/049,961, Examiner Interview Summary dated Oct. 30, 2014”, 3 pgs.
“U.S. Appl. No. 14/049,961, Non-Final Office Action dated Sep. 17, 2014”, 6 pgs.
“U.S. Appl. No. 14/049,961, Notice of Allowance dated Jan. 22, 2015”, 5 pgs.
“U.S. Appl. No. 14/049,961, Preliminary Amendment filed Oct. 9, 2013”, 6 pgs.
“U.S. Appl. No. 14/049,961, Preliminary Amendment filed Oct. 15, 2013”, 6 pgs.
“U.S. Appl. No. 14/049,961, Response filed Dec. 10, 2014 to Non-Final Office Action dated Sep. 17, 2014”, 6 pgs.
“U.S. Appl. No. 14/687,625, Non-Final Office Action dated Aug. 18, 2015”, 7 pgs.
“U.S. Appl. No. 14/687,625, Notice of Allowance dated Nov. 9, 2015”, 7 pgs.
“U.S. Appl. No. 14/687,625, Preliminary Amendment filed Apr. 15, 2015”, 6 pgs.
“U.S. Appl. No. 14/687,625, Preliminary Amendment filed Apr. 21, 2015”, 5 pgs.
“U.S. Appl. No. 14/687,625, Response filed Oct. 27, 2015 to Non-Final Office Action dated Aug. 18, 2015”, 7 pgs.
“U.S. Appl. No. 15/066,213, Non-Final Office Action dated Jan. 9, 2017”, 7 pgs.
“U.S. Appl. No. 15/066,213, Notice of Allowance dated May 8, 2017”, 5 pgs.
“U.S. Appl. No. 15/066,213, Preliminary Amendment filed Jul. 8, 2016”, 6 pgs.
“U.S. Appl. No. 15/066,213, Response filed Apr. 10, 2017 to Non-Final Office Action dated Jan. 9, 2017”, 6 pgs.
“U.S. Appl. No. 15/696,965, Non-Final Office Action dated Mar. 21, 2018”, 7 pgs.
“U.S. Appl. No. 15/696,965, Notice of Allowance dated Sep. 11, 2018”, 5 pgs.
“U.S. Appl. No. 15/696,965, Response filed Jun. 21, 2018 to Non-Final Office Action dated Mar. 21, 2018”, 7 pgs.
“International Application Serial No. PCT/US2006/044000, International Search Report dated Jul. 2, 2007”, 3 pgs.
Li, et al., “Hydroxyapatite coating by dipping method and bone bonding strength”, vol. 7. Materials Science Materials in Medicine, (1996), 355-357.
Related Publications (1)
Number Date Country
20190274791 A1 Sep 2019 US
Provisional Applications (1)
Number Date Country
61318641 Mar 2010 US
Continuations (5)
Number Date Country
Parent 15696965 Sep 2017 US
Child 16222231 US
Parent 15066213 Mar 2016 US
Child 15696965 US
Parent 14687625 Apr 2015 US
Child 15066213 US
Parent 14049961 Oct 2013 US
Child 14687625 US
Parent 13074670 Mar 2011 US
Child 14049961 US